Skip to main content
For Healthcare Professionals
Specialty_banner

Specialty

Boehringer Ingelheim specialty pioneering science inspired by patients we won’t rest until we can give people the chance to live the life they want.

ILDTalks PPF in HP EP.5: How do we treat fibrotic, progressive HP

26/03/2024  |  Author: Boehringer Ingelheim

Document ID: PC-TH-104586

Specialty

ILDPPF||ILDTalks PPF in iNSIP EP.1: iNSIP, what is it?
ILDPPF||ILDTalks PPF in iNSIP EP.2: How do we monitor patients with iNSIP?
ILDPPF||ILDTalks PPF in CTD-ILD EP.1: The importance of early referral for patients with CTD-ILD: a pulmonologists perspective
ILDPPF||ILDTalks PPF in iNSIP EP.3: What are the first line treatment options in iNSIP?
ILDPPF||ILDTalks PPF in iNSIP EP.4: How do we treat patients with iNSIP who develop PPF?
ILDPPF||ILDTalks PPF in iNSIP EP.5: How has nintedanib affected our treatment of patients?
ILDPPF||ILDTalks PPF in HP EP.1: Hypersensitivity pneumonitis: a distinct form of ILD?
ILDPPF||ILDTalks PPF in CTD-ILD EP.2: How do we monitor patients with CTD-ILD?
ILDPPF||ILDTalks PPF in HP EP.7: What does the future of HP treatment look like?
ILDPPF||ILDTalks PPF in CTD-ILD EP.3: Treatment of patients with PPF and CTD-ILD
ILDPPF||ILDTalks PPF in CTD-ILD EP.4: How does nintedanib fit in with background treatments for underlying CTDs?
ILDPPF||ILDTalks PPF in HP EP.2: Differentiation from IPF
ILDPPF||ILDTalks PPF in HP EP.3: What are the treatment options for HP?
ILDPPF||ILDTalks PPF in HP EP.4: How can we monitor for progression in our patients with HP
ILDPPF||ILDTalks PPF in HP EP.5: How do we treat fibrotic, progressive HP
ILDPPF||ILDTalks PPF in HP EP.6: Practical experience with nintedanib
ILDPPF||ILDTalks PPF in CTD-ILD EP.5: How do we keep patients on treatment with nintedanib?

RELATED CONTENT